期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 12, 期 3, 页码 576-592出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2015.1102809
关键词
anti-cancer drugs; HER3/ERBB3; monoclonal antibodies; receptor tyrosine kinase; signal transduction
资金
- European Research Council
- Seventh Framework Program of the European Commission (LungTarget Consortium)
- German-Israeli Project Cooperation (DIP)
- Israel Cancer Research Fund
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Cancer progression depends on stepwise accumulation of oncogenic mutations and a select group of growth factors essential for tumor growth, metastasis and angiogenesis. Agents blocking the epidermal growth factor receptor (EGFR, also called HER1 and ERBB1) and the co-receptor called HER2/ERBB2 have been approved over the last decade as anti-cancer drugs. Because the catalytically defective member of the family, HER3/ERBB3, plays critical roles in emergence of resistance of carcinomas to various drugs, current efforts focus on antibodies and other anti-HER3/ERBB3 agents, which we review herein with an emphasis on drug combinations and some unique biochemical features of HER3/ERBB3.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据